Docetaxel Teva (docetaxel)
- Region
- 🇪🇺 EU
- Active substance
- docetaxel
- Company
- Teva B.V.
- Status
- Withdrawn
- Therapeutic area
- Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Stomach Neoplasms; Breast Neoplasms
- CHMP opinion
- Thu 19 Nov 2009
- EU approval
- Tue 26 Jan 2010
- Designations
- Generic
- Application
- EMEA/H/C/001107
- ATC
- L01CD02
- Official record
- www.ema.europa.eu
Indication
Breast cancer Docetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: operable node-positive breast cancer; operable node-negative breast cancer. For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel Teva monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Non-small-cell lung cancer Docetaxel Teva is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy. Docetaxel Teva in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition. Prostate cancer Docetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Gastric adenocarcinoma Docetaxel Teva in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. Head and neck cancer Docetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Taxotere Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Docetaxel Kabi Authorised · Fresenius Kabi Deutschland GmbH
- 🇪🇺 Docetaxel Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Docetaxel Zentiva (previously Docetaxel Winthrop) Withdrawn · Zentiva k.s.
- 🇪🇺 Taxespira (previously Docetaxel Hospira UK Limited ) Withdrawn · Hospira UK Limited
- 🇪🇺 Docetaxel Mylan Lapsed · Mylan S.A.S.
- 🇪🇺 Docetaxel SUN Application withdrawn · Sun Pharmaceutical Industries Europe B.V.
- 🇪🇺 Docetaxel Teva Pharma Lapsed · Teva Pharma B.V.
- 🇪🇺 Docefrez Withdrawn · Sun Pharmaceutical Industries Europe B.V.
- 🇪🇺 Docetaxel Mylan Application withdrawn · Mylan S.A.S.
Follow Docetaxel Teva
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.